Login
ALX ONCOLOGY HOLDINGS INC logo

ALX ONCOLOGY HOLDINGS INC

alxoncology.com

What Do They Do?

Develops experimental cancer medicines, including an immune therapy and a targeted antibody-drug conjugate, for patients with breast, gastric and other cancers.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +1% (Loss)
vs −$22.1M in Q3 FY2025
  • Jun 29, 2026 Chairman Corey Goodman resigned; Scott Garland became chairman Goodman also left the board; Garland had served as an independent director.

A broader drug pipeline The pipeline has expanded beyond its lead immune-focused cancer drug candidate to include an antibody-linked cancer drug in clinical testing.

Who Do They Compete With?

Competes with Adagene, Akesobio, Bio-Thera Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Byondis, Centessa, Conjupro Biotherapeutics, CTTQ (SinoBiological), Daiichi Sankyo, Exelixis, GenSci, Gilead Sciences, Hanchor Bio, Hisun, Hutchmed, I-Mab, Ichnos, ImmuneOncia Therapeutics, and ImmuneOnco Biopharma

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support